Transforming care for patients as consumers

December 26, 2018

This white paper examines important conditions and trends driving consumerism, evidence of the economic and reputational value of a positive consumer experience, examples of health systems successfully improving the patient experience, and a Johnson & Johnson Medical Devices Companies approach to working with health systems to embrace the new era of consumerism.

Spotlight

Astellas Pharma

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category.

OTHER WHITEPAPERS
news image

2023 State of Cybersecurityfor Medical Devices andHealthcare Systems

whitePaper | August 7, 2023

Improving patient safety and protecting healthcare from cybersecurity threats is our top priority at Health-ISAC. The healthcare sector is essential to a country’s national security infrastructure. Cyber-attacks on healthcare systems can have broader implications for public health and national security.

Read More
news image

Clearing hurdles that crimp real-time and predictive insights in healthcare

whitePaper | July 26, 2022

Healthcare leaders have long recognized the importance of real-time decision making. Take, for instance, sepsis one of the leading causes of U.S. hospital deaths that costs the industry an estimated $62B a year,1 not to mention the preventable morbidity

Read More
news image

IMPROVING STRATEGIC SUPPLIER DISCOVERY THROUGH TECHNOLOGY

whitePaper | December 9, 2022

Procurement and sourcing are rapidly evolving to become much more strategic, with greater ability to significantly impact operational health.

Read More
news image

INDICATION-SPECIFIC PRICING OF PHARMACEUTICALS IN THE UNITED STATES HEALTH CARE SYSTEM

whitePaper | November 24, 2022

The 2015 ICER Policy Summit convened an influential group of evidence policy leaders from insurers, pharmacy benefit management firms.

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 3, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible.

Read More
news image

The importance for healthcare organizations to extend theprinciples of zero trust to business-critical applications

whitePaper | May 15, 2022

The zero trust security framework is predicated on the foundational concept that implicit trust of users and devices in the environment increases the risk of a potential compromise. By eliminating this implicit trust and requiring strict identification and authentication throughout the network

Read More

Spotlight

Astellas Pharma

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category.

Events